New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
08:21 EDTSQNM, FLDM, PKI, DDXS, WAT, PACB, AFFXMaxim recommends life science tools, diagnostics ahead of earnings
Maxim expects 2014 to be a "great year" for life science tools and diagnostics stocks and recommends buying Affymetrix (AFFX), diaDexus (DDXS), Fluidigm (FLDM), Pacific Biosciences (PACB), PerkinElmer (PKI), Sequenom (SQNM) and Waters (WAT) ahead of the Q4 results. Maxim has a preference for Pacific Biosciences, PerkinElmer and Waters. The firm raised its price target for Fluidigm to $52 from $42 and for Pacific Biosciences to $9 from $8.
News For AFFX;DDXS;FLDM;PACB;PKI;SQNM;WAT From The Last 14 Days
Check below for free stories on AFFX;DDXS;FLDM;PACB;PKI;SQNM;WAT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
08:32 EDTDDXSdiaDexus says Chief Business Officer Richey to leave company
diaDexus announced that Michael Richey, chief business officer, will be leaving the company effective September 30. The company has initiated a search for a chief commercial officer. Paul Manners will oversee the company's commercial operations in an interim role until the CCO role is filled. Manners was previously vice president, Global Finance and Marketing at Novartis Diagnostics and also held executive finance and commercial positions within Johnson & Johnsonís pharmaceutical and medical device businesses.
08:32 EDTDDXSdiaDexus names Kenneth Fang as Chief Medical Officer
Subscribe for More Information
07:05 EDTSQNMSequenom presents new data supporting accuracy of MaterniT21 test
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, presented patient clinical data substantiating the performance of its MaterniT21 PLUS noninvasive prenatal test in the laboratory. An ad hoc analysis of 185,000 samples from patients at high-risk for fetal chromosome aneuploidy demonstrated stable positivity rates for trisomy 21, 18 and 13, which mirror the positivity rates found in large studies on high-risk populations utilizing invasive diagnostic procedures. Additionally, Sequenom Laboratories reported performance results from clinical testing with the MaterniT21 PLUS test with Enhanced Sequencing Series. In the ad hoc analysis based on voluntary outcomes provided by clinicians, the estimated sensitivity for trisomy 21, 18 and 13 were 99.3%, 98.3% and 97.4% respectively, and the estimated specificity was >99.9% for all three trisomies. These clinical laboratory performance data are equivalent to those published in the clinical validation studies of the MaterniT21 test. Based on these performance metrics, Sequenom Laboratories estimates that the MaterniT21 PLUS test positive predictive value for trisomy 21, 18 and 13 were 99.0%, 97.6% and 92.8% respectively, and the negative predictive value was >99.9% for all three trisomies.
September 17, 2014
11:57 EDTSQNMSequenom management to meet with Maxim
Meetings to be held in New York on September 22 with a group luncheon also and in Boston on September 23 hosted by Maxim.
07:47 EDTFLDMFluidigm shares recommended at Maxim
Subscribe for More Information
September 16, 2014
10:44 EDTSQNMSequenom lost Inter Partes Review to Ariosa, says Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use